Mode
Text Size
Log in / Sign up
N/A N=36 Randomized Triple-blind Treatment

Encapsulated Mesenchymal Stem Cells for Dental Pulp Regeneration.

Periapical Periodontitis

Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Jan 2020
Primary outcome: Primary: Number of Participats Showing Efficacy (Functionality) — 18; 18 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Regenerative Endodontic Procedure (Procedure); Conventional Root Canal Treatment (Procedure)
Age
Pediatric, Adult · 16+ yrs
Sex
All
Sponsor
Universidad de los Andes, Chile
Primary completion
Sep 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participats Showing Efficacy (Functionality)
18; 18
SECONDARY
Change in Pulpal Response
1; 1; 17; 17; 0; 1
SECONDARY
Change in Apical Lesion Size
5; 5.5; 5.5; 7.1; 5; 5.1
SECONDARY
Pain to Percussion
11; 5; 7; 13; 1; 0
SECONDARY
Numbers of Participants With Adverse Event
0; 0; 0; 0
SECONDARY
Pulp Regeneration
60.6; 74.4; 78.1

Summary

To compare the dental survival in a period of one year of mature permanent teeth with apical lesion following the administration of encapsulated Mesenchymal Stem Cells under a regenerative endodontic procedure and a conventional root canal treatment.

Eligibility Criteria

Inclusion Criteria

Patient inclusion criteria:

  • Age: 16 - 58 years old.
  • Signed the informed consent.
  • Non-smoking.
  • Systemically healthy patients

Tooth inclusion criteria:

  • Upper and lower incisors, upper and lower canines and lower premolars teeth with mature apex and apical lesion (greater than 2 PAI and 1 CBCTPAI).
  • Teeth that do not response to both electrical and thermal pulp test
  • Teeth that can be restored (as defined by Class A or Class B using Samet and Jotkowitz classification) without the need of a stainless steel crown.

Exclusion Criteria

Patient exclusion criteria:

  • Patients without a phone number for contact during the study.
  • Subjects not available for follow up period (12 months).
  • Patients who are or will undergo orthodontic treatment over the next 12 months.
  • Patients with an allergy to any material or drug used in the study.
  • Patients who are pregnant or lactating.
  • Patients with a history of systemic diseases that alter immune function, such as diabetes mellitus, immunodeficiency, leukemia, Addison's disease and Cushing.
  • Patients who have used immunosuppressive drugs or chemotherapy, 3 months before the study.

Tooth exclusion criteria:

  • Endodontically treated teeth
  • Teeth with signs of severe root resorption.
  • Teeth with mobility class III or Dens invaginatus.
  • Teeth with avulsion history and conservation in a dry extraoral medium for more than 1 hour.
  • Teeth with clinical and / or radiographic evidence of root fracture.
  • Teeth that can not be absolutely isolated with rubber dam. . Teeth with more than one root or root canal.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03102879). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search